6.5 C
New York
Saturday, May 28, 2022

Cheap Antidepressant Fluvoxamine Shows Promise Treating Severe Covid-19

Must Read

They Just Discovered A New Ancestor Of Human Beings

If you've ever been interested in learning more about your family tree, you'll find this news intriguing....

Three strange food cravings could be early dementia warning flags

Dementia cases are on the rise, largely as a result of individuals living longer lives. Early detection...

West Virginia woman kills party shooter – Police

Police claim a female partygoer halted a potential mass massacre in the United States when she drew...
Jiya Saini
Jiya Saini is a Journalist and Writer at Revyuh.com. She has been working with us since January 2018. After studying at Jamia Millia University, she is fascinated by smart lifestyle and smart living. She covers technology, games, sports and smart living, as well as good experience in press relations. She is also a freelance trainer for macOS and iOS, and In the past, she has worked with various online news magazines in India and Singapore. Email: jiya (at) revyuh (dot) com

In a meta-analysis looking for existing drugs that could be repurposed to treat coronavirus, Fluvoxamine – a low-cost antidepressant reduced the need for hospitalization among high-risk adults with COVID-19.

The drug, which is used to treat depression and obsessive-compulsive disorder, was put to the test since it was known to lower inflammation and had shown promise in smaller studies.

For a course of COVID-19 treatment, the medication, fluvoxamine, would cost $4. Antibody IV therapies cost around $2,000, while Merck’s investigational COVID-19 antiviral tablet costs around $700 per course. Some scientists believe that various medicines will be used in tandem to combat the coronavirus in the future.

In this paper, the researchers assessed the combined results of three trials including more than 2000 participants, and found there was a 94.1 per cent to 98.6 per cent chance the drug had an impact on hospitalization numbers when used as an early COVID-19 treatment.

They say Fluvoxamine could be a more widely accessible option to supplement the use of other treatments, particularly where supply is low.

These findings imply that fluvoxamine, a widely available and low-cost therapy for COVID-19 outpatients, was linked to fewer hospitalizations.

The results of the study were published today in the JAMA Network Open.

There are still questions about the appropriate dosing, whether lower-risk patients could benefit, and whether the pill should be used in conjunction with other therapies.

While clinicians do not need FDA approval to prescribe fluvoxamine for emergency use, they may be reticent to do so unless the National Institutes of Health recommends it in its Covid-19 treatment guidelines.

According to the NIH, “there is insufficient evidence . . . to recommend either for or against the use of fluvoxamine for the treatment of COVID-19.”

Source: 10.1001/jamanetworkopen.2022.6269

Image Credit: Getty

You were reading: Cheap Antidepressant Fluvoxamine Shows Promise Treating Severe Covid-19

- Advertisement -
- Advertisement -

Latest News

- Advertisement -

More Articles Like This

- Advertisement -